SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

July 14, 2011 11:01 ET

Radient Pharmaceuticals Selects RCRI as Reimbursement Specialist

Supporting Commercialization in US for FDA Cleared Indication

TUSTIN, CA--(Marketwire - Jul 14, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced today it has selected Regulatory and Clinical Research, Inc. (RCRI) as its specialist consultants on reimbursement and healthcare economics.

RCRI will provide its expertise to Radient in building broader reimbursement from public and private payers for the Company's Onko-Sure® cancer IVD, which is cleared by the FDA for colorectal cancer monitoring of treatment and recurrence. Effectively navigating the reimbursement landscape is an important part of a product's success in the US market. The team at RCRI has worked with the Centers for Medicare and Medicaid Services and numerous private payers at the local and national level. They have obtained CPT codes and trained sales and marketing teams.

RCRI has helped more than 400 medical device, IVD, and bioscience companies worldwide translate their medical device plans into successful revenue generating businesses. RCRI is ISO 9001: 2008 certified to provide expertise in regulatory affairs, clinical trial design and management, database development, reimbursement strategy, health economics, quality systems and compliance, biostatistics, and venture capital due diligence.

"Clinical studies show that Onko-Sure® helps detect cancer earlier. Not only does this significantly improve patient outcomes and survival rate, it also reduces costs for the public and private organizations that pay for healthcare," stated Radient's CEO, Mr. Douglas MacLellan. "RCRI will help us make our case to insurers that it is to the insurer's and the patient's benefit to have Onko-Sure® widely reimbursed."

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics.

RPC's Business Metrics
Cash on hand: $1.4 million*
*Approximate amount as of July 11, 2011
Shares Outstanding: 177 million*
*Approximate number as of July 11, 2011 and there are 200 million shares fully authorized.
Outstanding Warrants & Options: 111.1 million*
*Approximate number as of July 11, 2011

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.